Measles-mumps-rubella vaccine has been approved in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Measles-Mumps-Rubella Vaccine studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
209762/147 (MeMuRu-147) IV Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18 months in Singapore.
209762/149 (MeMuRu-149) IV Phase IV, single-blind, randomised, multicenter study to evaluate the immediate post-vaccination pain, reactogenicity and tolerance of GlaxoSmithKline Biologicals’ Measles-Mumps-Rubella vaccine (Priorix®) administered as a second dose compared to Aventis-Pasteur-MSD’s Measles-Mumps-Rubella vaccine (ROR Vax®). Priorix®: GlaxoSmithKline Biologicals’ Measles-Mumps-Rubella vaccine (MMR) ROR Vax®: Sanofi-Aventis-MSD’s (formerly Aventis-Pasteur-MSD) Measles-Mumps-Rubella vaccine (ROR)
209762-145 (MeMuRu-145) IV A phase IV, open, multicentric, post-marketing surveillance study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ live attenuated Measles-Mumps-Rubella vaccine (Priorix™) in Korean subjects administered according to the Prescribing Information. Priorix™ (MMR): GlaxoSmithKline Biologicals’ live attenuated Measles-Mumps-Rubella vaccine.
209762/136 (MeMuRu-136) III A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals'* MMR vaccine (PRIORIX®) and comparability of PRIORIX with Merck's M-M-R® II vaccine, administered to healthy children 12 to 18 months of age. *SmithKline Beecham Biologicals is currently GlaxoSmithKline (GSK) Biologicals
209762/146 (MMR-146) III Open, multicentre study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated Measles-Mumps-Rubella vaccine (Priorix™) given to healthy children at the age of 12 to 15 months or 4- 6 years. Priorix™ (MMR): GlaxoSmithKline Biologicals’ live attenuated Measles-Mumps-Rubella vaccine.
209762/150 III Double blind, randomized sequential study to compare the immunogenicity and reactogenicity of the current formulations of GSK Biologicals’ measles-mumps-rubella vaccine (Priorix™) and GSK Biologicals’ varicella vaccine (Varilrix™) to investigational vaccination regimens. Priorix™: GlaxoSmithKline (GSK) Biologicals’ combined measles-mumps-rubella vaccine (MMR) Varilrix™: GSK Biologicals’ varicella vaccine (Varicella)
104420 II A phase II study to evaluate the persistence of measles, mumps and rubella antibodies two years after the single dose primary vaccination in study 209762/151.
209762/148 (MeMuRu-148) II Phase II, double blind, randomized sequential study to compare the immunogenicity and reactogenicity of the current formulations of GSK Biologicals’ measles-mumps-rubella vaccine (Priorix™) and GSK Biologicals’ varicella vaccine (Varilrix™) containing human serum albumin (HSA) with the modified formulations which do not contain HSA (Priorix-mf and Varilrix-mf, respectively).
209762/151 II Phase II, randomized, controlled study to evaluate the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ investigational vaccination regimen compared to the currently licensed GlaxoSmithKline Biologicals’ Priorix™ and Merck and Co.’s M-M-R®II vaccines when administered as a primary vaccination to healthy children aged 12-24 months. MMR (Priorix): combined measles-mumps-rubella vaccine ; M-M-R®II: MMR-II